Harvard Bioscience (HBIO) Misses Q4 EPS by 10c

Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of ($0.06), $0.10 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $23.1 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Dingdong (DDL) Reports Q2 EPS of RMB0.90
• Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline